Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02966756 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02966756 · ClinicalTrials.gov record · last posted 2026-08-19

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
SponsorAbbVie
Started2017-10-12
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2).

Protocol amendment history 4 changes detected by DataLookout

2026-08-20
Enrollment closed, study ongoing
2026-08-20
Enrollment reduced: 110 → 66 participants
2026-08-20
Primary completion pushed: 2029-05 → 2030-12
2026-08-20
Completion pushed: 2029-05 → 2030-12
Trial Details
NCT Number NCT02966756
Lead Sponsor AbbVie
Conditions Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Enrollment 66 participants
Start Date 2017-10-12
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-19